Molecular size distribution of somatostatin-like immunoreactivity in the cerebroventricular fluid of neurosurgical patients.
The molecular size distribution of somatostatin-like immunoreactivity (SLI) in the cerebroventricular fluid of patients with Parkinson's disease, dystonic syndromes, multiple sclerosis, basal and midline tumors, epilepsy and pain syndromes was investigated by separation with a Sephadex G-50f column and subsequent radioimmunoassay of the eluate. Marked heterogeneity of SLI was observed in most of the pools investigated. The most conspicuous feature of the elution profiles was the preponderance of the peak coeluting with synthetic somatostatin-14, whereas the peaks comigrating with synthetic somatostatin-28 and attributable to precursor-like SLI represented only minor or trace amounts of total immunoreactivity. These findings are consistent with the greater biological activity of somatostatin-14 in the human central nervous system, whereas somatostatin-28 appears to represent the more active form in the pituitary and in the intestinal mucosa. Solely in the case of brain tumor patients, some differences could be seen, resulting in an approximately equal distribution of somatostatin-14 and somatostatin-28 in two pools of ventricular fluid and by the detection of a degradation product of somatostatin-14 in another one. These observations could be explained by a lowered barrier function as a consequence of increased intracranial pressure in case of brain tumors, which is well in accordance with a markedly elevated total protein content being a sign of a lowered barrier function.
Rissler
K
K
Department of Neurology and Clinical Neurophysiology, University of Freiburg, F.R.G.
Jost
S
S
Mohadjer
M
M
Mundinger
F
F
Cramer
H
H
D000293:Adolescent; D000328:Adult; D001826:Body Fluids / Q000032:analysis; D001927:Brain Diseases / Q000378:metabolism*; D002552:Cerebral Ventricles / Q000032:analysis*; D002648:Child; D004421:Dystonia / Q000378:metabolism; D006801:Humans; D008875:Middle Aged; D008970:Molecular Weight; D010300:Parkinson Disease / Q000378:metabolism; D010455:Peptides / Q000032:analysis*; D011863:Radioimmunoassay
D010455:Peptides; C029993:somatostatin-like peptides